RevOpsis and Kemwell Form Manufacturing Partnership for nAMD

RevOpsis Therapeutics and Kemwell Biopharma have forged a strategic manufacturing partnership aimed at accelerating the development of RO-104, a pioneering tri-specific biologic designed by RevOpsis for treating neovascular age-related macular degeneration (nAMD).

Neovascular age-related macular degeneration (nAMD) is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp, central vision needed for activities like reading and driving. It occurs when abnormal blood vessels grow underneath the macula and leak blood and fluid, leading to rapid and severe vision loss if left untreated.

Targeting Multiple Angiogenic Pathways

RO-104 targets three critical angiogenic pathways—VEGF-A, VEGF-C, and Ang-2—simultaneously, positioning it as a first-in-class fully human monotherapy biologic. This capability marks a significant advancement in the treatment landscape for retinal vascular diseases, particularly nAMD, which remains a leading cause of global blindness.

Kemwell Biopharma, recognized as India's first commercial current Good Manufacturing Practices (cGMP) facility, brings extensive expertise in complex protein manufacturing to the collaboration. This partnership harnesses Kemwell's established track record in biologics manufacturing excellence and integrates it with RevOpsis' innovative Rev-Mod platform. This platform is renowned for its ability to facilitate the rapid development of multispecific biologics.

Strategic Significance and Mission Alignment

Ram Bhandari, MD, Co-founder and Interim CEO of RevOpsis, highlighted the strategic significance of partnering with Kemwell: "This collaboration is pivotal in accelerating the development of RO-104 and advancing our pipeline of innovative multispecific biologics. Kemwell's expertise in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, enables us to deliver transformative therapies efficiently. Our mission is to develop groundbreaking treatments and bring our innovations to patients worldwide."

Anurag Bagaria, CEO of Kemwell Biopharma, expressed enthusiasm about the collaboration: "We are excited to collaborate with RevOpsis to manufacture and commercialize RO-104. Our expertise in complex protein manufacturing, coupled with RevOpsis' innovative therapeutic approaches, holds great promise for advancing the treatment of retinal vascular diseases. This partnership underscores our commitment to delivering high-quality biologics for patients in need."

Accelerating Therapeutic Discovery

The partnership between RevOpsis and Kemwell represents a significant step towards transitioning from pre-clinical activities to first-in-human clinical trials for RO-104 and other potential biologics in RevOpsis' pipeline. By combining RevOpsis' plug-and-play multispecific biologics platform with Kemwell's deep biologics development and manufacturing knowledge, the collaboration aims to accelerate therapeutic discovery timelines leading up to IND submissions.

About RO-104

RO-104, developed on RevOpsis' Rev-Mod platform, is a modular tri-specific biologic engineered to address VEGF-A, VEGF-C, and Ang-2 pathways implicated in retinal vascular disease progression, including nAMD. Supported by robust preclinical evidence demonstrating efficacy and safety in animal models, RO-104 represents a transformative approach poised to redefine standards of care for nAMD patients worldwide.